Latest Docetaxel Stories
The first randomized trial to investigate the use of trastuzumab emtansine (T-DM1) – an antibody-guided drug – for the initial treatment of HER2- (human epidermal growth factor receptor-2) positive metastatic breast cancer has shown that it makes a significant difference to the time women live without their disease worsening.
Premiere Oncology today announced that it is participating in a Phase 2b/3 clinical trial of ganetespib, a novel, potent anti-cancer drug in combination with docetaxel, an approved chemotherapy
TARRYTOWN, N.Y., July 7, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
THOUSAND OAKS, Calif., June 27, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S.
BOTHELL, Wash. and VANCOUVER, British Columbia, June 6, 2011 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc.
PARIS and TARRYTOWN, N.Y., June 6, 2011 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc.
HORSHAM, Pa., May 25, 2011 /PRNewswire/ -- A study titled "Abiraterone and Increased Survival in Metastatic Prostate Cancer," published in the May 26 issue of NEJM, found that patients with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel showed a significant improvement in overall survival when treated with ZYTIGA(TM) (abiraterone acetate) plus prednisone compared to patients treated with prednisone plus placebo.
- An uxorious, effeminate, or spiritless man.
- A timorous, cowardly fellow.